• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of new biomarkers for the detection of plaque rupture in patients with cervical internal carotid artery stenosis

Research Project

Project/Area Number 20K17920
Research Category

Grant-in-Aid for Early-Career Scientists

Allocation TypeMulti-year Fund
Review Section Basic Section 56010:Neurosurgery-related
Research InstitutionNiigata University

Principal Investigator

Ando Kazuhiro  新潟大学, 脳研究所, 非常勤講師 (20849004)

Project Period (FY) 2020-04-01 – 2023-03-31
Project Status Completed (Fiscal Year 2022)
Budget Amount *help
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2022: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2021: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2020: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
KeywordsPodoplanine / CLEC-2 / 静脈血栓塞栓症 / 悪性神経膠腫 / ポドプラニン / 頚動脈プラーク / リンパ管 / 静脈血栓症 / 可溶型CLEC-2 / 動脈硬化 / 深部静脈血栓症・肺塞栓症 / 頚動脈狭窄症
Outline of Research at the Start

頚部内頚動脈狭窄症は,狭窄部に生じるプラークがし,塞栓子(血栓)が飛散して脳梗塞を引き起こす.現在,プラークの性状は評価可能であるが,「破綻」を同定することは不可能である.動脈硬化部分でポドプラニンというタンパク質が増加しており,これに結合する血小板受容体CLEC-2 (C-type lectin-like receptor 2)は,ポドプラニンと結合することで活性化し可溶型となって遊離する.本研究では,対象者から採取した血液中のポドプラニン値と可溶型CLEC-2値を測定し上昇していることを証明することでプラークの「破綻」を同定し,脳梗塞のリスク評価として新たなバイオマーカーを確立する.

Outline of Final Research Achievements

In this study, we found that the sCLEC-2 level and C2PAC index tended to be higher in patients with IDH-wildtype high grade gliomas, which were suggested that the platelet activation was enhanced. In addition, we found that platelet activation is strongly involved in the development of VTE in patients with IDH-wildtype high grade gliomas as well as the coagulation system, which may be useful for elucidation the pathology of VTE and providing a new biomarker for VTE associated with IDH-wildtype high grade gliomas.

Academic Significance and Societal Importance of the Research Achievements

本研究の結果は術後に可溶型 CLEC-2 値を評価することで静脈血栓塞栓症合併をより 早期に予知・発見するが可能となり,臨床におけるより安全な術後管理に寄与できることが期待されます。

Report

(4 results)
  • 2022 Annual Research Report   Final Research Report ( PDF )
  • 2021 Research-status Report
  • 2020 Research-status Report
  • Research Products

    (4 results)

All 2023 2021 2020

All Journal Article (1 results) (of which Peer Reviewed: 1 results) Presentation (1 results) Patent(Industrial Property Rights) (2 results)

  • [Journal Article] Elevated ratio of C-type lectin-like receptor 2 level and platelet count (C2PAC) aids in the diagnosis of post-operative venous thromboembolism in IDH-wildtype gliomas2023

    • Author(s)
      Ando Kazuhiro、Natsumeda Manabu、Kawamura Masahide、Shirakawa Kamon、Okada Masayasu、Tsukamoto Yoshihiro、Eda Takeyoshi、Watanabe Jun、Saito Shoji、Takahashi Haruhiko、Kakita Akiyoshi、Oishi Makoto、Fujii Yukihiko
    • Journal Title

      Thrombosis Research

      Volume: 223 Pages: 36-43

    • DOI

      10.1016/j.thromres.2023.01.018

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed
  • [Presentation] 可溶型CLEC-2による悪性神経膠腫術後静脈血栓塞栓症の病態解明とモニタリングの可能性2021

    • Author(s)
      安藤和弘
    • Organizer
      第80回日本脳神経外科学会総会
    • Related Report
      2021 Research-status Report
  • [Patent(Industrial Property Rights)] 可溶型CLEC2を用いた癌患者における血栓症リスクの予測方法2021

    • Inventor(s)
      藤井 幸彦
    • Industrial Property Rights Holder
      LSIメディエンス
    • Industrial Property Rights Type
      特許
    • Filing Date
      2021
    • Acquisition Date
      2021
    • Related Report
      2021 Research-status Report
  • [Patent(Industrial Property Rights)] 可溶型LEC2を用いた癌患者における血栓症リスクの予測方法2020

    • Inventor(s)
      藤井幸彦
    • Industrial Property Rights Holder
      藤井幸彦
    • Industrial Property Rights Type
      特許
    • Filing Date
      2020
    • Acquisition Date
      2020
    • Related Report
      2020 Research-status Report

URL: 

Published: 2020-04-28   Modified: 2024-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi